Showing 7921-7930 of 10904 results for "".
Hoya ConBio - Vascular Lesions
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/hoya-conbio-vascular-lesions/19454/Vascular Lesions that aren't successfully removed by other treatments are usually successfully removed with the Medlite Laser. Instructions and ideal settings for the laser are discussed.Dr. Ross Discusses Experience with Gemini Laser
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dr-ross-discusses-experience-with-gemini-laser/19470/“There are a lot of new technologies out there, but one of the tried-and-true technologies is KTP laser and the long-pulse YAG laser. And the Gemini fits the bill for both of those wavelengths. So in a sense the Gemini is a time-tested product. It has served us well at our clinic, both at the NavyEducating NPs and PAs
https://practicaldermatology.com/programs/practical-dermatology/educating-nps-and-pas/39884/Jennifer Cather, MD, and Melodie Young ASN, RN, discuss recent consensus statements from the Genital Psoriasis Wellness Consortium, and Scott Boswell, MD, joins Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, to discuss his boot camp for nurse practitioners and phyPromising Therapies on the Atopic Dermatitis Horizon
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37178/Justin Marson, MD, Chief Resident 2024-25 in the Department of Dermatology at SUNY Downstate Health Science University, previews important potential developments in the atopic dermatitis pipelineISDPA: Dr. Bhatia on JAK Inhibitors
https://practicaldermatology.com/conferences/isdpa-midwest-derm-2024/isdpa-dr-bhatia-jak-inhibitors/27064/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, talks about his presentation on JAK inhibitors at the Illinois Society of Dermatology Physician Assistants (ISDPA) Midwest Dermatology Conference 2024.Practical Dermatology Roundtable: Reclaiming Urticaria, Ch. 3
https://practicaldermatology.com/programs/practical-dermatology/practical-dermatology-roundtable-reclaiming-urticaria-ch-3/84988/In the third installment of this five-part series, Brad P. Glick, DO, MPH, FAAD; Laura K. Ferris, MD, PhD; and Lawrence J. Green, MD, FAAD, examine the immunologic pathways underlying CSU, including mast-cell activation, IgE and IgG mechanisms, BTK inhibition, and distinctions from chronic inducibleWhy Lower-Frequency Dosing Can Be Helpful in Atopic Dermatitis
https://practicaldermatology.com/programs/practical-dermatology/why-lower-frequency-dosing-can-be-helpful-in-atopic-dermatitis/70394/In the fourth installment of this five-part series, Naiem T. Issa, MD, PhD, FAAD, and Maureen N. Offiah, MD, FAAD, describe the importance of a lower-frequency dosing option in treatment for chronic atopic dermatitis.Connections for the Future of Dermatology
https://practicaldermatology.com/videos/skin-minute/connections-for-the-future-of-dermatology/54688/Frederick Beddingfield, MD, PhD, recaps the Dermatology Summit 2026, a meeting to connect innovators and investors in the field of dermatology.DWTV Extra: Raising Awareness of GPP
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-raising-awareness-of-gpp/56366/Shannon Trotter, DO, discusses the importance of awareness of generalized pustular psoriasis (GPP) and targeting IL-36, as well as GPP Awareness Day in August.DWTV Extra: Rocatinlimab Trials
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-rocatinlimab-trials/39044/Clinical investigator Emma Guttman-Yassky, MD, PhD, discusses two sets of data presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025. The phase 3 ROCKET-Ignite Trial evaluated the efficacy and safety of OX40-receptor targeting with rocatinlimab in moderate-to-severe a